-

12:39:44 PM

ABUS Stock News

ABUS - Arbutus Biopharma Corp

05/17/22 7:30 AM

Nasdaq : ABUS

conferences

Arbutus to Present at H.C. Wainwright Global Investment Conference

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arbutus’

RHEA-AI

neutral

05/05/22 7:30 AM

Nasdaq : ABUS

earnings

Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update

RHEA-AI

neutral

04/21/22 7:30 AM

Nasdaq : ABUS

conferencesearnings

Arbutus to Report First Quarter 2022 Financial Results and Provide Corporate Update

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its

RHEA-AI

neutral

03/03/22 7:30 AM

Nasdaq : ABUS

earnings

Arbutus Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

Anticipate reporting data from four clinical trials in chronically infected HBV patients in 2022 Expected to complete IND-enabling studies for two oral compounds (PD-L1 inhibitor AB-101 and RNA destabilizer AB-161) to treat HBV in the second half of 2022 Anticipate advancing an oral compound that

RHEA-AI

neutral

02/28/22 6:02 AM

Nasdaq : ABUS

Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Genevant Sciences today filed a lawsuit in

RHEA-AI

negative

02/17/22 7:30 AM

Nasdaq : ABUS

conferencesearnings

Arbutus to Report Fourth Quarter and Year End 2021 Financial Results and Provide Corporate Update

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its

RHEA-AI

neutral

01/24/22 7:30 AM

Nasdaq : ABUS

Arbutus Announces 2022 Corporate Objectives and Provides Financial Update

Multiple AB-729 and AB-836 HBV clinical data readouts anticipated to guide future clinical development and regulatory strategies Complete IND-enabling studies for oral PD-L1 inhibitor, AB-101, for the treatment of HBV Complete IND-enabling studies for next generation oral RNA destabilizer, AB-161,

RHEA-AI

neutral

01/04/22 7:30 AM

Nasdaq : ABUS

conferences

Arbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with

RHEA-AI

neutral

12/14/21 7:30 AM

Nasdaq : ABUS

clinical trial

Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection

Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV)

RHEA-AI

neutral

12/13/21 7:30 AM

Nasdaq : ABUS

partnership

Arbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan

Qilu Pharmaceutical, one of the leading pharmaceutical companies in China, becomes strategic partner to provide development, manufacturing and commercialization expertise for the mainland China, Hong Kong, Macau and Taiwan markets Arbutus to receive $40 million in an upfront payment, up to $245

RHEA-AI

positive

1 2 3 4 5 6 Next

ABUS Data

IndustryPharmaceutical Preparation Manufacturing
Websitearbutusbio.com
CeoWilliam Collier
Security nameArbutus Biopharma Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees77
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address701 Veterans Circle
StatePennsylvania
CityWarminster
Zip18974
CountryUS
Phone12674690914

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).